Market Overview

UPDATE: Oppenheimer Initiates Quest Diagnostics at Underperform on Restructuring, Industry Risks

Share:
Related DGX
Bank of America Downgrades Quest Diagnostics To Underperform
Benzinga's Top Downgrades

Oppenheimer initiated coverage on Quest Diagnostics (NYSE: DGX) with an Underperform rating and a $53.00 price target.

Oppenheimer noted, "While management is taking steps to streamline the company's operations, we believe the industry's headwinds will overshadow progress in the near term. Although a 4.95% reimbursement cut is on the table, if sequestration is averted, we think the industry may have to absorb an even greater pricing decline in a grand bargain scenario. We estimate that, even with the company's proposed cost reductions, reimbursement headwinds will still dominate. With volume growth trailing the industry and cost cutting a multi-year process, we believe the shares of DGX will trail its primary competitor."

Quest Diagnostics closed at $57.94 on Monday.

Latest Ratings for DGX

DateFirmActionFromTo
Feb 2015Bank of AmericaDowngradesNeutralUnderperform
Jan 2015CitigroupMaintainsNeutral
Jan 2015Wells FargoDowngradesMarket PerformUnderperform

View More Analyst Ratings for DGX
View the Latest Analyst Ratings

Posted-In: OppenheimerAnalyst Color Initiation Analyst Ratings

 

Related Articles (DGX)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga PRO content